VITAL BIOTECH<08193> - Results Announcement (Q3, 2002, Summary) Vital BioTech Holdings Limited announced on 08/11/2002: (stock code: 08193) Year end date :31/12/2002 Currency :HKD Auditors' report :N/A Review of 3rd Quarterly Report by :Audit Committee Important Note : This result announcement form only contains extracted information from and should be read in conjunction with the detailed results announcement of the issuer, which can be viewed on the GEM website at http://www.hkgem.com (Unaudited) (Unaudited) Current Last Corresponding Period Period from 01/01/2002 from 01/01/2001 to 30/09/2002 to 30/09/2001 $'000 $'000 Turnover : 106,522 79,197 Profit/(Loss) from Operations : 29,583 24,400 Finance cost : (2,186) (1,891) Share of Profit/(Loss) of Associates : N/A N/A Share of Profit/(Loss) of Jointly Controlled Entites : N/A N/A Profit/(Loss) after Taxation & MI : 24,097 22,267 % Change Over the Last Period : +8.22% EPS / (LPS) Basic (in dollar) : HKD 0.0206 HKD 0.0232 Diluted (in dollar) : HKD 0.0206 HKD 0.0232 Extraordinary (ETD) Gain/(Loss) : N/A N/A Profit (Loss) after ETD Items : 24,097 22,267 3rd Quarterly Dividends per Share : NIL NIL (specify if with other options) : N/A N/A B/C Dates for 3rd Quarterly Dividends : N/A Payable Date : N/A B/C Dates for (-) General Meeting : N/A Other Distribution for Current Period : NIL B/C Dates for Other Distribution : N/A For and on behalf of Vital BioTech Holdings Limited Signature : Name : Lam Kai Cheung Title : Company Secretary Responsibility statement The directors of the Company (the "Directors") as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this results announcement form (the "Information") and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information are accurate and complete in all material respects and not misleading and that there are no other matters the omission of which would make the Information herein inaccurate or misleading. The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information. Remarks: 1. Group reorganisation and basis of preparation Pursuant to a group reorganisation (the "Group Reorganisation") to rationalise the group structure in preparation for the listing of the Company's shares on the Growth Enterprises Market of The Stock Exchange of Hong Kong Limited (the "Stock Exchange"), the Company became the holding company of the subsidiaries (collectively the "Group"). The Group Reorganisation was completed on 26 January 2002 and the shares of the Company were listed on the Stock Exchange on 7 February 2002. According to the provisions of SSAP No. 27 ¡¥Accounting for the group reconstructions¡¦issued by the Hong Kong Society of Accountants, the structure of the Group can be regarded as in existence in the past. The third quarterly report of the Group was unaudited. The third quarter financial statements of the Group have been reviewed by the audit committee of the Group. 2. Turnover The Group is principally engaged in biotechnology research, manufacturing and trading of pharmaceutical products. Turnover represents invoiced sales net of return goods, discounts allowed, sales taxes or value added taxes, where applicable. 3. Earnings per share The calculation of the basic earnings per shares is based on the profit attributable to shareholders of approximately HK$24,097,000 (2001: HK$22,267,000) and weighted average of approximately 1,168,775,000 (2001: 960,000,000) ordinary shares in issue during the period, and with the assumption that the Group Reorganisation had been completed on 1 January 2001. On 21 June 2002, the Board granted share options to subscribe for 30,000,000 ordinary shares of the Company. The grantees are entitled to exercise portion of the share options commencing 16 August 2002 to 6 February 2012 to subscribe for approximately 6,850,000 shares. The dilution effect of such ordinary shares to earnings per share for the 9 months ended 30 September 2002 is not material and no diluted earnings per share (2001: nil) is presented. 4. Dividend The Board did not recommend the payment of an interim dividend for the quarter ended 30 September 2002 (2001: nil). |